A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Phase 3
366
about 8.7 years
12–17
39 sites in AL, AZ, CA +19
What this study is about
This trial is testing a treatment called Deucravacitinib in adolescents with moderate to severe plaque psoriasis. The goal is to see if this treatment helps improve the condition, and also to understand its safety and how it affects drug levels in the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Deucravacitinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
deucravacitinib
oral (Oral Tablet)
Secondary: Body weight, Change from baseline in Children's Dermatology Life Quality Index (CDLQI) score, Change from baseline in PASI, Change from baseline in body surface area (BSA) involvement, Change from baseline in worst itch numeric rating scale (WI-NRS), Height, Number of participants achieving ≥ 4 improvement from baseline in the WI-NRS score (in participants with baseline score ≥ 4), Number of participants with serious adverse events
Dermatology